DRAFT May 2017

PPCPs (Pharmaceuticals and Personal Care Products): Ethinylestradiol (Estrogen)

Ethinylestradiol, also known as estrogen, is a steroidal drug that affects the hormones in the human body. Ethinylestradiol is used to supplement or replace the body's natural estrogen. It helps to relieve many of the problems associated with the menopause, such as hot flushes, night sweats and vaginal dryness. The drug is typically prescribed for females (Chrousos 2012).

In April 2016 the ECOTOX database had 300 articles from 1970-2016 that focused of the effects of ethinylestradiol. The most common effects are feminization, gonadal development and sexual development. The most susceptible wildlife to ethinylestradiol are fish and water fleas.

Reported effects of ethinylestradiol from toxicity literature in the ECOTOX database (as of April 2016)

| Aquatic Life | Reported Most | Reported Common | Reported Toxicity Value (LOEC, NOEC, EC50, LC50) |
|-----------------|---------------------|-----------------------|--|
| | Common effect(s) | study endpoint(s) | |
| Zebrafish | Feminization, | Sex Changes, Egg | EC50: Zebrafish: 1.04 mg/L (Schiller 2014), |
| | reduced egg | Production, Behavior, | LOEC (fertility/maturity/fecundity): 1.1 ng/L (1st generation), 2 ng/L |
| | production, | Reproduction, | (2nd generation) |
| | aggressive behavior | Gonadal, | NOEC: 0.72 ng/L (Rose 2002), |
| | | Physiological, | 96h LC50: 1.7 mg/L (Versonnen 2003) |
| Medaka | Increased cells in | Fertilization, | LOEC: 0.2 ng/L (Ma 2007), |
| | liver, endocrine | Absorption, | EC50: Zebrafish: 1.04 mg/L (Schiller 2014), |
| | effects | Endocrine disruption, | LC50: None reported (Cho 2005), |
| | | reproduction, VTG, | LOEL: 0.0001 ug/L, |
| | | Liver | NOEL: <0.0001 ug/L (Metcalfe 2001) |
| Crustacean | Effects not visible | survival, | NOEC & LOEC & LC50 (10 d & 21 d): >100 ug/L (Pounds 2002), |
| | in low | development and | |
| | concentration, low | reproduction | |
| | survival | | |
| Water Fleas and | No mortality, | Reproduction, | LOEC, NOEC, LC50: >100 ug/L (Hutchinson 1999), |
| other related | reduced fecundity, | Endocrine, Hormones | EC50 (mg/L): 0.088 (Andersen 2001) |
| invertebrates | nonspecific | | |
| | biomarker | | |
| | responses | | |
| Frogs | feminization, | Sexual Development, | LC50 (R. pipens-2 wks): Development: 3.01 uM (stage 26), 4.17(stage |
| | disrupted sexual | Sex ratio, gonadal | 36), Post-Hatch: 2.75 uM / R. slyvatica: 1.89 uM/ (Hogan 2006) |
| | development, sex | | EC50: 7.7 ug/L (Thompsett 2013) |
| | reversal, | | |
| Other fishes | Lower sperm | Gene expression, | LOEC: 1.0 ng/L (Experiment 1), 7.6 ng/L (Experiment 2) / |
| | count, | development, | NOEC: 0.21 ng/L (Experiment 1), 1.1 ng/L (Experiment 2) (Thorpe 2003 |
| | feminization, | reproduction, | |
| | diminished survival | hormones | |
| Alligator | significant female | Developmental, sex | Significant effects occurred at low dosage (0.1 and 0.3 mg/kg and |
| | gonadal | determination, hatch | ug/kg)(Matter 1998) |
| | differentiation at | rate | |
| | low dosage, low | | |
| | hatching rate | | |

Chrousos, G.P. (2012) The gonadal hormones and inhibitors in B.G. Katzung, S.B. Masters. A.J. Trevor, 12 Eds. Basic and clinical pharmacology. McGraw Hill. New York, NY, pp. 719